| Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. | |
| | |
MedLine Citation:
|
PMID: 21180598 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder that causes a range of symptoms. Currently, alosetron hydrochloride (Lotronex®), a selective serotonin type 3 receptor antagonist, is the only medication approved for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have inadequately responded to conventional therapy. Alosetron has demonstrated efficacy compared with placebo in clinical trials and has been shown to improve overall health-related quality of life (HRQoL). However, rare instances of ischemic colitis and severe complications of constipation have been reported. As a result, in 2000 alosetron was voluntarily withdrawn from the market but was reintroduced in 2002 with a more restricted indication and a requirement that clinicians and patients follow a prescribing program. Although the efficacy and benefit of alosetron has been clearly demonstrated, it has been used sparingly since its reintroduction. This brief review describes the history of alosetron, efficacy of alosetron in the treatment of IBS, the impact of severe IBS on HRQoL, safety considerations, the risk evaluation and mitigation strategy program under which alosetron is now prescribed, and an update on postmarketing surveillance data. |
| | |
Authors:
|
Susan L Lucak |
Related Documents
:
|
20453578 - Clinical report: a male with down syndrome, fragile x syndrome, and autism. 10900928 - Phenotypic checklist to screen for fragile x syndrome in people with mental retardation. 2051558 - Horner syndrome: a rare complication of internal jugular vein cannulation. 10331588 - Frequency of the fragile x syndrome in chinese mentally retarded populations is similar... 22351068 - Synaptic pathology of down syndrome. 20458608 - Spontaneous anterior interosseous nerve palsy with churg-strauss syndrome. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Therapeutic advances in gastroenterology Volume: 3 ISSN: 1756-2848 ISO Abbreviation: Therap Adv Gastroenterol Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-12-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101478893 Medline TA: Therap Adv Gastroenterol Country: England |
Other Details:
|
Languages: eng Pagination: 165-72 Citation Subset: - |
Affiliation:
|
Assistant Professor of Clinical Medicine, Department of Medicine, Division of Digestive and Liver Diseases, College of Physicians & Surgeons of Columbia University, Columbia-Presbyterian Medical Center, 630 West 168th Street, Room PH 20-319, Box 83, New York, NY 10032, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Functional dyspepsia.
Next Document: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective.